Channing Capital Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-54,244
Closed -$8.79M 115
2024
Q3
$8.79M Sell
54,244
-4,077
-7% -$650K 0.22% 81
2024
Q2
$8.52M Buy
58,321
+5,291
+10% +$787K 0.23% 79
2024
Q1
$8.39M Sell
53,030
-112
-0.2% -$17.8K 0.23% 80
2023
Q4
$8.33M Buy
53,142
+2,692
+5% +$413K 0.25% 72
2023
Q3
$7.86M Buy
50,450
+4,858
+11% +$802K 0.26% 66
2023
Q2
$7.55M Buy
45,592
+723
+2% +$117K 0.23% 76
2023
Q1
$6.95M Buy
+44,869
New +$7.25M 0.22% 88
2016
Q1
Sell
-14,132
Closed -$1.45M 103
2015
Q4
$1.45M Sell
14,132
-25,698
-65% -$2.58M 0.06% 95
2015
Q3
$3.72M Hold
39,830
0.18% 94
2015
Q2
$3.88M Sell
39,830
-9,684
-20% -$970K 0.17% 91
2015
Q1
$4.98M Sell
49,514
-1,361
-3% -$138K 0.23% 84
2014
Q4
$5.32M Buy
50,875
+9,226
+22% +$972K 0.27% 83
2014
Q3
$4.44M Hold
41,649
0.27% 87
2014
Q2
$4.36M Hold
41,649
0.26% 89
2014
Q1
$4.09M Hold
41,649
0.26% 91
2013
Q4
$3.81M Hold
41,649
0.25% 88
2013
Q3
$3.61M Hold
41,649
0.27% 89
2013
Q2
$3.58M Buy
+41,649
New +$3.53M 0.32% 89

Other funds holding JNJ

Channing Capital Management's JNJ Position: Q4 2024 in Review

Channing Capital Management sold out of Johnson & Johnson (JNJ) in Q4 2024, closing a stake of 54,244 shares — an estimated $8.79M sold.

Channing Capital Management first reported a position in JNJ in Q2 2013 and held it in 18 quarters. The position peaked at $8.79M in Q3 2024. 4,104 funds tracked by Wall St. Rank hold JNJ as of Q4 2024.

  • Channing Capital Management reported no remaining Johnson & Johnson position as of Q4 2024 after selling out during the quarter.
  • Channing Capital Management sold 54,244 Johnson & Johnson shares in Q4 2024, an estimated $8.79M.
  • Channing Capital Management first reported a position in Johnson & Johnson in Q2 2013 and held it in 18 quarters.
  • Channing Capital Management's Johnson & Johnson position peaked at $8.79M in Q3 2024.
  • 4,104 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2024.

Based on Channing Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.